Healthcare
Live Price
Offline$100.00
+2.23% today
1Y Change
+5.32%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Revvity, Inc. (RVTY) is a Healthcare stock with a market cap of $9.67B and listed on NYSE. The stock last traded around $100.00 and up 5.3% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +3.7%, EPS growth of -13.7%, a dividend yield of 0.3%. What stands out right now is revenue +3.7%, EPS -13.7%, free cash flow -6.2% with operating margin 13.0% and ROIC 2.9%. The dividend is present but secondary, with a yield around 0.3%. Valuation already assumes a fairly strong business story at P/E 40.5 and price/sales 3.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RVTY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RVTY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RVTY Max Drawdown
-30.14%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RVTY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$3.8B
+15.6% YoY
FY Net Income
$943.2M
+65.7% YoY
Free Cash Flow
$1.3B
+123.0% YoY
Revenue Growth
+3.7%
EPS Growth
-13.7%
Gross Margin
50.2%
Net Margin
8.5%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 2.9B | 2.8B | 2.8B | 3.3B | 3.8B |
| Gross Profit | 1.5B | 1.3B | 1.3B | 1.8B | 2.3B |
| Operating Income | 357M | 411M | 399M | 781M | 1.3B |
| EBITDA | 663M | 840M | 714M | 1.2B | 1.6B |
| Net Income | 242M | 296M | -118M | 569M | 943M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 920M | 1.2B | 913M | 454M | 603M |
| Total Assets | 12.2B | 12.4B | 13.6B | 14.1B | 15.0B |
| Total Liabilities | 4.9B | 4.7B | 5.7B | 6.7B | 7.9B |
| Shareholder Equity | 7.3B | 7.7B | 7.9B | 7.4B | 7.1B |
| Total Debt | 3.5B | 3.3B | 4.1B | 4.6B | 5.2B |
| Net Debt | 2.6B | 2.2B | 3.2B | 4.1B | 4.6B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1.4B
+107.5% YoY
Capital Expenditures
86M
-0.5% YoY
Free Cash Flow
1.3B
+123.0% YoY
Key ratios
Gross Margin
50.2%
Operating Margin
13.0%
Net Margin
8.5%
ROE
3.2%
Debt / Equity
0.48x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.